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Diffuse Intrinsic Pontine Glioma (DIPG) is a
glial tumor occurring primarily in children and so
far, has seen very low survival rates. DIPG makes
up about 10% of all childhood central nervous
system tumors and occurs in the pons, a part of the
brainstem. Due to its critical location, surgery is not
an option as the brainstem controls many important
bodily functions such as breathing and blood
pressure. This paired with the fact that DIPG
tumors tend to grow at an aggressive rate gives
need to the development of novel therapeutics.
DIPG tumors possess a key mutation in
Histone 3, H3K27M mutation (a substitution
mutation of lysine for methionine at position 27 of
Histone H3) existent within 80% of DIPGs. This
mutation inhibits the activity of the Polycomb
repressive complex 2 (PRC2), which promotes the
H3K27trimethyl (me3) mark on chromatin and an
increase in the activating H3K27acetyl (ac) mark.
As a result of increased K27 acetylation, there is an
activation of oncogenic pathways and further tumor
cell proliferation.
Interestingly, a chromatin remodeler, RE1
silencing transcription factor (REST) is highly
elevated in DIPGs (Fig 1). REST functions with
other chromatin remodelers, G9a, lysine-specific
demethylase 1 (LSD1), and histone deacetylase
1/2 (HDAC1/2) to modify the expression. DIPG
cells with a H3K27M mutation have higher levels of
REST. Both in vitro and in vivo assays have shown
that a decrease in REST leads to a loss of tumor
vasculature as well as a substantial decline in
tumor cell growth (Shaik et a., 2007). Thus, we
propose that targeting REST is a therapeutic
approach.

Methods

Cell Culture: DIPG cell lines used include
(DIPG-IV, -VII, and -XIII) (expressing the
H3.1K27M, wildtype (WT), and H3.3 K27M,
respectively.
Isogenic
DIPG
cells
engineered to express higher-REST levels
were also used in the assays. All DIPG cell
lines were grown in DIPG cell culture media
with added growth factors (Shaik et al.,
2017).
ATP Assay: *All materials used in ATP
Assay come from the PerkinElmer ATPlite
assay system* Cells were plated in 96 wells
plate. Following 120 hours of incubation
with JQ1 or UNC0638, cells were lysed with
50 uL (per well) mammalian cell lysis buffer
and then added 50uL (per well) substrate
buffer solution, mixed and incubated under
dark conditions before measuring the
luminescence in the Luminometer.

Results

A concentration-dependent decrease in the
growth of both DIPG-IV-GFP and DIPG-IVGFP-REST was observed with JQ1. At 1
µM concentration, cell growth in both cell
lines was decreased to 75% compared to
their respective controls (Fig 2.)
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Fig. 3 A-C: DIPG-IV, DIPG-VII and DIPG-XIII (IGFP
and GFP-REST) cells were treated with JQ1 for 120
hrs and cell growth was determined by ATP assay.
n=3; Cell growth was compared between untreated
and JQ1 treated cells. *p<0.05; **p<0.01; ***p<0.001;
###p<0.001; DIPG-VII
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Fig. 1: Human DIPG tumors show increased REST
expression in comparison to normal. REST is elevated in
DIPGs with H3K27M mutation (Shaik et al., 2017,
Oncotarget).
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Hypothesis

We hypothesized that targeting the RESTassociated G9a chromatin remodeler alone or in
combination with a drug that blocks the activity
of the histone H3K27 acetyl mark-BRD4 will
decrease the growth of DIPG cells.

Fig. 2 A-C. : DIPG-IV, DIPG-VII and DIPG-XIII (IGFP
and GFP-REST) cells were treated with UNC0638 for
120 hrs and cell growth was determined by ATP assay.
Cell growth was compared between GFP and GFPREST cells, respectively. n=3. *p<0.05; **p<0.01;
***p<0.001;

The experimental data was analyzed
using student’s t test. The significance
was taken when the p value between
two experimental groups were less
than
*p<0.05,
**p<0.01
and
***p<0.001.
JQ1 treatment resulted in a significant
decrease in cell growth with a 75%
decrease in DIPG-IV (GFP and GFPREST) at 1 µM concentration.
UNC0638 resulted in a decrease in
cell growth in a REST-dependent
manner only in DIPG-IV cell lines,
having very minimal effect on DIPGVII. The DIPG-XIII cells (GFP and
GFP-REST) exhibited a 50% decrease
in cell growth at 1 µM concentration.
The combination of UNC0638 and JQ1
treatments indicated that DIPG-GFPREST cell growth was decreased to
38% when used the combination of
drug doses of 0.25 µM of UNC0638
and 0.1 µM of JQ1 compared to 1%
with DIPG-IV-GFP cells.

Fig. 5. DIPG-IV (GFP and GFP-REST) cells were
treated with various concentrations of UNC0638 and
0.1 µM of JQ1 for 120 hrs and cell growth was
determined by ATP assay...

UNC0638 treatment promoted a RESTdependent,
statistically
significant,
reduction in cell growth only in DIPG IV
cells.
A decrease in cell growth following JQ1
treatment was seen in all cells but was
REST-independent.
The combination of UNC0638 and JQ1
did not result in a synergistic decrease in
cell growth in high or low-REST DIPG
cells compared to either drug alone.
In parallel, a REST-context specific
chemical screen was performed, which
identified new therapeutic vulnerabilities.
These will be investigated in future
studies.
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